These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2391701)

  • 1. Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines.
    Atwal KS; Rovnyak GC; Kimball SD; Floyd DM; Moreland S; Swanson BN; Gougoutas JZ; Schwartz J; Smillie KM; Malley MF
    J Med Chem; 1990 Sep; 33(9):2629-35. PubMed ID: 2391701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyrimidine calcium channel blockers: 2-heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines.
    Atwal KS; Rovnyak GC; Schwartz J; Moreland S; Hedberg A; Gougoutas JZ; Malley MF; Floyd DM
    J Med Chem; 1990 May; 33(5):1510-5. PubMed ID: 2329573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of novel calcium channel blockers: 2,5-dihydro-4-methyl-2-phenyl-1,5-benzothiazepine-3-carboxylic acid esters and 2,5-dihydro-4-methyl-2-phenyl-1,5-benzodiazepine-3-carboxylic acid esters.
    Atwal KS; Bergey JL; Hedberg A; Moreland S
    J Med Chem; 1987 Apr; 30(4):635-40. PubMed ID: 2435903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents.
    Rovnyak GC; Atwal KS; Hedberg A; Kimball SD; Moreland S; Gougoutas JZ; O'Reilly BC; Schwartz J; Malley MF
    J Med Chem; 1992 Aug; 35(17):3254-63. PubMed ID: 1387168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents.
    Atwal KS; Swanson BN; Unger SE; Floyd DM; Moreland S; Hedberg A; O'Reilly BC
    J Med Chem; 1991 Feb; 34(2):806-11. PubMed ID: 1995904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibitory action of Biginelli-type dihydropyrimidines on depolarization-induced arterial smooth muscle contraction.
    Cernecka H; Veizerova L; Mensikova L; Svetlik J; Krenek P
    J Pharm Pharmacol; 2012 May; 64(5):735-41. PubMed ID: 22471370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium channel blocking and positive inotropic activities of ethyl 5-cyano-1,4-dihydro-6-methyl-2-[(phenylsulfonyl)methyl]-4-aryl-3- pyridine-carboxylate and analogues. Synthesis and structure-activity relationships.
    Sircar I; Gregor EK; Anderson KR; Haleen SJ; Shih YH; Weishaar RE; Steffen RP; Pugsley TA; Taylor MD
    J Med Chem; 1991 Jul; 34(7):2248-60. PubMed ID: 2066997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing dichloroimidazolyl substituents.
    Amini M; Golabchifar AA; Dehpour AR; Pirali HM; Shafiee A
    Arzneimittelforschung; 2002; 52(1):21-6. PubMed ID: 11838270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imidazo[1,5-a]pyrimidine and benzo[4,5]imidazo-[1,2-a]pyrimidine derivatives as calcium antagonists.
    Alajarin R; Vaquero JJ; Alvarez-Builla J; de Casa-Juana MF; Sunkel C; Priego JG; Gomez-Sal P; Torres R
    Bioorg Med Chem; 1994 May; 2(5):323-9. PubMed ID: 7922143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators.
    Rovnyak GC; Kimball SD; Beyer B; Cucinotta G; DiMarco JD; Gougoutas J; Hedberg A; Malley M; McCarthy JP; Zhang R
    J Med Chem; 1995 Jan; 38(1):119-29. PubMed ID: 7837222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active conformation of 1,4-dihydropyridine calcium entry blockers. Effect of size of 2-aryl substituent on rotameric equilibria and receptor binding.
    Rovnyak G; Andersen N; Gougoutas J; Hedberg A; Kimball SD; Malley M; Moreland S; Porubcan M; Pudzianowski A
    J Med Chem; 1991 Aug; 34(8):2521-4. PubMed ID: 1652021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and smooth muscle calcium channel effects of dialkyl 1,4-dihydro-2,6-dimethyl-4-aryl-3,5-pyridinedicarboxylates containing a nitrone moiety in the 4-aryl substituent.
    Anana RD; Ng H; Howlett SE; Knaus EE
    Arch Pharm (Weinheim); 1997 Mar; 330(3):53-8. PubMed ID: 9167447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of new N3-substituted dihydropyrimidine derivatives as L-/T- type calcium channel blockers.
    Teleb M; Zhang FX; Farghaly AM; Aboul Wafa OM; Fronczek FR; Zamponi GW; Fahmy H
    Eur J Med Chem; 2017 Jul; 134():52-61. PubMed ID: 28399450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain.
    Teleb M; Zhang FX; Huang J; Gadotti VM; Farghaly AM; AboulWafa OM; Zamponi GW; Fahmy H
    Bioorg Med Chem; 2017 Mar; 25(6):1926-1938. PubMed ID: 28233679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers.
    Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR
    Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity.
    Cho H; Ueda M; Shima K; Mizuno A; Hayashimatsu M; Ohnaka Y; Takeuchi Y; Hamaguchi M; Aisaka K; Hidaka T
    J Med Chem; 1989 Oct; 32(10):2399-406. PubMed ID: 2552119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing lipophilic 4-imidazolyl substituents.
    Navidpour L; Miri R; Shafiee A
    Arzneimittelforschung; 2004; 54(9):499-504. PubMed ID: 15500195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and calcium channel antagonist activity of dialkyl 4- (dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylates.
    Dagnino L; Li-Kwong-Ken MC; Wynn H; Wolowyk MW; Triggle CR; Knaus EE
    J Med Chem; 1987 Apr; 30(4):640-6. PubMed ID: 3560157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on nilvadipine. I. Synthesis and structure-activity relationships of 1,4-dihydropyridines containing novel substituents at the 2-position.
    Satoh Y; Ichihashi M; Okumura K
    Chem Pharm Bull (Tokyo); 1991 Dec; 39(12):3189-201. PubMed ID: 1814611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of some new C2 substituted dihydropyrimidines and their electrophysiological evaluation as L-/T-type calcium channel blockers.
    Teleb M; Rizk OH; Zhang FX; Fronczek FR; Zamponi GW; Fahmy H
    Bioorg Chem; 2019 Jul; 88():102915. PubMed ID: 31005784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.